International Stem Cell (International Stem Cell) Accounts Payable & Accrued Expense : $0.94 Mil (As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Accounts Payable & Accrued Expense?

International Stem Cell's quarterly accounts payable & accrued expense increased from Sep. 2023 ($0.75 Mil) to Dec. 2023 ($0.85 Mil) and increased from Dec. 2023 ($0.85 Mil) to Mar. 2024 ($0.94 Mil).

International Stem Cell's annual accounts payable & accrued expense declined from Dec. 2021 ($0.91 Mil) to Dec. 2022 ($0.83 Mil) but then increased from Dec. 2022 ($0.83 Mil) to Dec. 2023 ($0.85 Mil).

International Stem Cell Accounts Payable & Accrued Expense Historical Data

The historical data trend for International Stem Cell's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Accounts Payable & Accrued Expense Chart

International Stem Cell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.30

0.75

0.91

0.83

0.85

International Stem Cell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															0.98	0.85	0.75	0.85	0.94

International Stem Cell Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

International Stem Cell (International Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website

https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

Executives

Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin	10 percent owner	1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova	officer: Dir. of Legal Affairs & Oper.	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don	director	2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens	officer: Acting Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi	officer: Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin	director, 10 percent owner	2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak	officer: Interim CFO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw	officer: Executive Vice President	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund	director	C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc	10 percent owner	5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May	officer: President and COO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen	officer: Chief Financial Officer	5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus	director, officer: President	2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027